Transcranial Magnetic Stimulation Versus Ketamine in Treatment-Resistant Depression: A Critical Narrative Review (2025)

Treatment-resistant depression (TRD) remains one of the most challenging mental health conditions to treat, often requiring advanced, evidence-based approaches when traditional medications fail. Two leading options are Transcranial Magnetic Stimulation (TMS) and ketamine therapy, both showing promising results in patients who have not responded to standard antidepressants. At Neurotherapy Montreal, we specialize in innovative, non-invasive mental health treatments, including private depression treatment, designed to help patients achieve lasting improvement. This article offers a critical, research-based comparison of TMS versus ketamine for TRD in 2025, exploring how each works, their effectiveness, potential side effects, and how to choose the right approach for your needs.

Abstract

Objective: To compare the efficacy, speed of action, durability of response, safety/tolerability, and practical considerations of rTMS/TBS versus ketamine/esketamine in treatment-resistant depression (TRD).

Methods: A narrative review of meta-analyses, RCTs, and observational studies (2019–2025), focusing on network analyses and maintenance data.

Results: Recent network analyses show overall comparable antidepressant efficacy between rTMS/TBS and ketamine, with no clear differences in response/remission rates; acceptability may be slightly higher for IV ketamine, but evidence certainty remains low. Ketamine stands out for its rapid action (24–72 hours) and acute anti-suicidal effect. rTMS/TBS stands out for its favorable systemic tolerability and growing relapse prevention data. Maintenance data exist for esketamine (open-label, long-term) and rTMS (RCTs in relapse prevention) but are heterogeneous. Sequential or combined approaches are promising but lack standardized protocols.

 PMC+1Nature+1JAMA Network

Introduction

TRD (defined as failure of at least two adequate antidepressant trials) affects a substantial portion of patients and is associated with high morbidity. Canadian guidelines (CANMAT 2023) recognize both rTMS/TBS and ketamine/esketamine as evidence-based options for TRD. PMCPubMed

Comparative Efficacy Data

Antidepressant Efficacy (Response and Remission)

Two major 2025 analyses are foundational:

  1. A 2025 network meta-analysis comparing IV ketamine, rTMS, and ECT found no significant differences in response/remission between IV ketamine and rTMS (quality of evidence: low to very low); acceptability (treatment-related discontinuation) seemed more favorable for IV ketamine.

  2. Another 2025 NMA focused on TRD showed robust effects for TBS, rTMS, and ketamine among non-traditional options, suggesting overall comparable population-level efficacy. PMCNature

Direct comparisons remain rare. One small naturalistic study (IM ketamine vs rTMS) reported similar acute effects but had methodological limitations (small size, non-randomized). PMC

Speed of Action

Ketamine (IV) and esketamine (IN, as an add-on to an antidepressant) show clinical improvements within 24–72 hours, including rapid reduction of suicidal thoughts. rTMS/TBS typically takes 2–4 weeks (though this can be accelerated via TBS/“SAINT” protocols), making it slower but with a progressive onset. PMC

Durability and Maintenance
  • Esketamine: Open-label extension data (SUSTAIN-3) over several years indicate sustained efficacy for some patients using weekly or biweekly regimens (with oral antidepressants). Limitations: no control group, selection bias.
  • rTMS: A 2025 RCT found rTMS maintenance to be non-inferior to lithium in preventing relapse after initial response (75 TRD patients), supporting non-pharmacological maintenance strategies. JAMA Network

Tolerability and Safety
  • rTMS/TBS: Most side effects are local (headaches, scalp discomfort); seizure risk is extremely low under approved parameters. No systemic effects, no sedation, and no post-session monitoring required.
  • Ketamine/Esketamine: Can cause dissociation, dizziness, nausea, and transient increases in blood pressure/heart rate. Requires 60–120 minutes of post-dose monitoring in certified facilities (for esketamine). Long-term safety data are generally reassuring but mostly from open-label studies. Caution advised in patients at risk for substance use. PMCMDPI

Special Considerations

  • Theta-Burst Stimulation (TBS): Comparable efficacy to standard rTMS with much shorter session times (~3 minutes), improving accessibility and operational costs. PMC
  • rTMS Augmentation: In TRD, augmenting treatment with rTMS may outperform switching to a different SSRI/SNRI (effectiveness RCT, 2024). Nature

Suicidal Ideation and Cognition

  • Ketamine: Demonstrated rapid anti-suicidal effects in TRD (supported by RCTs and observational data), a key advantage when speed is critical.

  • rTMS: Shows positive signals but typically less immediate; neutral or potentially beneficial for cognitive function, whereas ketamine may induce transient dissociation. PMC

Combination and Sequential Approaches

Combined (rTMS + ketamine) or sequential treatments have shown substantial and sometimes longer-lasting improvements in case series and retrospective studies. However, due to heterogeneity and small sample sizes, caution is needed. No standard protocols are currently established. PMC

Guidelines and Clinical Algorithm Placement

CANMAT 2023 guidelines position both rTMS/TBS and ketamine/esketamine as valid options after pharmacological failures, within a personalized approach that considers speed of action, comorbidities, patient preferences, and treatment accessibility. PubMed

Practical Considerations for Clinicians

Clinical Situation

Ketamine / Esketamine

rTMS / TBS

Need for very rapid relief (e.g. suicidal ideation, severe distress)

Major asset (24–72h) with monitoring

Gradual efficacy (days to weeks)

Systemic tolerability

Dissociative effects, transient cardiovascular changes; supervision required

Very favorable profile; no sedation

Maintenance / relapse prevention

Long-term open-label data (esketamine); weekly/biweekly regimens

RCT data for prevention; maintenance sessions possible

Contraindications / risks

Caution in uncontrolled hypertension, substance use, pregnancy

Rare seizure risk; relative CIs (e.g. uncontrolled epilepsy)

Access constraints

Certified centers, monitoring time

Frequent but brief sessions (TBS ~3 min)

Synthesis based on sources cited in the text. PMC+2PMC+2JAMA Network

Pragmatic Recommendations (2025)

  1. If speed is critical (e.g., suicide risk, severe melancholic depression): consider IV ketamine or IN esketamine + antidepressant, with maintenance plan and cardiovascular/cognitive monitoring.

  2. If tolerability and absence of systemic effects are priorities, or if cardiovascular comorbidities make ketamine less ideal: favor rTMS/TBS; consider augmentation rather than switching medications.

  3. If one treatment fails, switching to the other is reasonable; combination therapy may be explored in experienced centers, with awareness that this is off-protocol.

  4. Plan for maintenance from the start: maintenance rTMS or spaced-out esketamine, based on modality and patient response. PMCJAMA Network

Limitations of the Evidence

  • Few direct head-to-head RCTs comparing rTMS and ketamine.
  • Much data is heterogeneous (protocols, doses, TRD definitions).

Overall evidence certainty often rated as “low” in network analyses, highlighting the need for large-scale pragmatic RCTs. PMC

Conclusion

As of 2025, both rTMS/TBS and ketamine/esketamine are effective options for TRD. The choice should be based on desired speed of action, tolerability, comorbidities, logistical access, and patient preferences. A flexible care pathway—including sequential and, when appropriate, combined approaches—appears most suitable in clinical practice, pending large-scale comparative RCTs and standardized maintenance protocols. NaturePubMed

Key References (Selection)

  1. Terao I, et al. Comparative efficacy and safety of IV ketamine, rTMS, and ECT in ≥Stage 2 TRD: Network meta-analysis (2025) PMC
  2. Saelens J, et al. Relative effectiveness of antidepressant treatments in TRD: Network meta-analysis (2025). Nature
  3. Nuñez NA, et al. Update on IV ketamine efficacy (rapid/anti-suicidal effects) (2023). PMC
  4. Zaki N, et al. Esketamine long-term extension SUSTAIN-3 (2023–2025). NaturePMC
  5. Noda Y, et al. rTMS as maintenance to prevent TRD relapse: RCT (2025). JAMA Network
  6. Papakostas GI, et al. rTMS augmentation vs antidepressant switch: Effectiveness RCT (2024). Nature
  7. Tao X, et al. Meta-analysis of rTMS vs TBS: Similar efficacy, time savings (2025). PMC
  8. CANMAT (Lam RW, 2023/2024) Guidelines for MDD/TRD. PubMed